{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:51:46Z","timestamp":1784260306851,"version":"3.55.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the appropriateness of laboratory testing intervals and antiphospholipid syndrome (APS) incidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between January 2010 and August 2022, insurance claims data of patients with disease codes for other thrombophilia (D68.6) and APS (V253) were retrieved in South Korea. Patients who received antiphospholipid antibody tests more than twice were classified as having suspected APS. The interval between the first 2 antiphospholipid antibody tests was evaluated in the patients with suspected APS. Patients with suspected APS who received anticoagulants for &amp;gt;180 days were classified as having APS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 8656 patients were classified as having suspected APS. The testing interval for the first 2 tests in patients with suspected APS was &amp;lt;6 and &amp;lt;12 weeks in 11.1% and 20.6% of cases, respectively, in 2010, gradually increasing to 21.0% and 35.4%, respectively, in 2021. Subsequently, 4344 patients were classified as having APS, with 65.0% being female. Only 330 patients were diagnosed with APS in 2021, down from 436 in 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study showed a gradual increase in patients receiving antiphospholipid antibody testing with an inappropriate short-term interval, underscoring the need for laboratory stewardship to ensure an appropriate interval for APS testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmae025","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:44:04Z","timestamp":1713177844000},"page":"627-632","source":"Crossref","is-referenced-by-count":1,"title":["Current status of testing intervals for antiphospholipid syndrome testing: a 13-year retrospective national data analysis in South Korea"],"prefix":"10.1093","volume":"55","author":[{"given":"Se-eun","family":"Koo","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University of Ulsan College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Hong","sequence":"additional","affiliation":[{"name":"Samkwang Medical Laboratories , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-4946","authenticated-orcid":false,"given":"Kuenyoul","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Sanggye Paik Hospital, School of Medicine, Inje University , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongsoo","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024090405513636100_CIT0001","first-page":"295","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume-title":"J Thromb Haemost.","author":"Miyakis","year":"2006"},{"key":"2024090405513636100_CIT0002","first-page":"e35","article-title":"Epidemiology of antiphospholipid syndrome in Korea: a nationwide population-based study","volume-title":"J Korean Med Sci.","author":"Hwang","year":"2020"},{"key":"2024090405513636100_CIT0003","first-page":"1545","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume-title":"Arthritis Rheumatol","author":"Duarte-Garc\u00eda","year":"2019"},{"key":"2024090405513636100_CIT0004","first-page":"2828","article-title":"Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume-title":"J Thromb Haemost.","author":"Devreese","year":"2020"},{"key":"2024090405513636100_CIT0005","first-page":"2641526","article-title":"Clinical application of revised laboratory classification criteria for antiphospholipid antibody syndrome: is the follow-up interval of 12 weeks instead of 6 weeks significantly useful","volume-title":"Biomed Res Int.","author":"Park","year":"2016"},{"key":"2024090405513636100_CIT0006","first-page":"718","article-title":"Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume-title":"J Korean Med Sci.","author":"Kim","year":"2017"},{"key":"2024090405513636100_CIT0007","first-page":"1309","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop","volume-title":"Arthritis Rheum.","author":"Wilson","year":"1999"},{"key":"2024090405513636100_CIT0008","first-page":"4152","article-title":"Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus","volume-title":"Blood.","author":"Male","year":"2005"},{"key":"2024090405513636100_CIT0009","first-page":"1461","article-title":"Appropriate utilization of clinical laboratory tests","volume-title":"Clin Chem Lab Med.","author":"Alonso-Cerezo","year":"2009"},{"key":"2024090405513636100_CIT0010","first-page":"85","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume-title":"Curr Rheumatol Rep.","author":"Dabit","year":"2022"},{"key":"2024090405513636100_CIT0011","first-page":"50","article-title":"The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: a 14-year nationwide population-based study","volume-title":"Thromb J","author":"Yao","year":"2022"},{"key":"2024090405513636100_CIT0012","first-page":"1314","article-title":"COVID-19 and resilience of healthcare systems in ten countries","volume-title":"Nat Med.","author":"Arsenault","year":"2022"},{"key":"2024090405513636100_CIT0013","first-page":"101402","article-title":"COVID-19 and antiphospholipid antibodies","volume-title":"Best Pract Res Clin Haematol.","author":"Butt","year":"2022"},{"key":"2024090405513636100_CIT0014","first-page":"e001580","article-title":"Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review","volume-title":"RMD Open","author":"Taha","year":"2021"},{"key":"2024090405513636100_CIT0015","first-page":"2191","article-title":"Antiphospholipid antibodies in patients with COVID-19: a relevant observation","volume-title":"J Thromb Haemost.","author":"Devreese","year":"2020"},{"key":"2024090405513636100_CIT0016","first-page":"102822","article-title":"Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent","volume-title":"Autoimmun Rev.","author":"Vollmer","year":"2021"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/5\/627\/58985538\/lmae025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/55\/5\/627\/58985538\/lmae025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T23:30:40Z","timestamp":1725492640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/55\/5\/627\/7645769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,15]]},"published-print":{"date-parts":[[2024,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae025","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,4,15]]}}}